The FDA has approved Scholar Rock's Isembyld (apitegromab) as the first muscle-targeted therapy for spinal muscular atrophy (SMA). Approved for adults and children aged two and older, the drug blocks myostatin to improve motor function. Scholar Rock plans an immediate launch with a net annual cost of approximately $310,000 per patient, though the actual price depends on weight. The approval follows a year-long delay caused by manufacturing issues that were resolved in August 2026.
Isembyld FDA approval for SMA
- ▪The Food and Drug Administration approved Scholar Rock's drug Isembyld for use alongside existing targeted therapies in adults and children at least 2 years of age
- ▪The Food and Drug Administration approved Scholar Rock's drug apitegromab, branded as Isembyld, on Friday, September 11, 2026, to treat spinal muscular atrophy
- ▪Scholar Rock immediately commenced the commercial launch of its spinal muscular atrophy drug Isembyld following its approval on Friday, September 11, 2026
Myostatin-blocking mechanism
- ▪Scholar Rock's drug Isembyld is approved for spinal muscular atrophy patients who are currently receiving therapies that target the SMN2 gene
- ▪Scholar Rock's drug Isembyld is a muscle-targeted treatment that blocks myostatin, a protein that limits muscle growth, to increase muscle mass and strength
Clinical efficacy motor function
- ▪In a late-stage clinical trial, Scholar Rock's drug Isembyld combined with standard therapy significantly improved patients' motor function compared to typical care or a placebo
- ▪Prescribing information for Scholar Rock's drug Isembyld includes a warning about an unexpected risk of bone fractures, which primarily affected patients with pre-existing risk factors
- ▪Side effects linked to Scholar Rock's drug Isembyld include upper respiratory tract infections, vomiting, viral infections, and headaches
Pricing $310,000 annually
- ▪The wholesale acquisition cost for a single-use vial of Scholar Rock's spinal muscular atrophy drug Isembyld is $11,659
- ▪Scholar Rock announced that the net annual cost of its spinal muscular atrophy drug Isembyld will be approximately $310,000 for a typical patient
- ▪The actual annual cost of Scholar Rock's drug Isembyld will vary based on a patient's weight and insurance coverage
Market potential $2 billion
- ▪Scholar Rock was awarded a priority review voucher by the Food and Drug Administration, which can speed up future drug evaluations or be sold
- ▪Analysts at Leerink Partners predicted that Scholar Rock's spinal muscular atrophy drug Isembyld could generate approximately $2 billion in peak annual sales
Manufacturing facility regulatory delays
- ▪Scholar Rock resolved regulatory delays by removing the troubled fill-finish facility from its application and adding an alternate plant in August 2026
- ▪The Food and Drug Administration rejected Scholar Rock's drug Isembyld in September 2025 due to issues observed at a manufacturing facility conducting fill-finish services
Debatable claims
- ▪The $310,000 annual price of Scholar Rock's Isembyld is justified
- ▪Insurers should cover Isembyld alongside existing expensive SMA therapies
Story comments
Loading comments…